| | |  | | | | Record from Web of Science® | | | | | | |
| Gene expression profiling predicts clinical outcome of breast cancer |
|
|
| Author(s): van't Veer LJ, Dai HY, van de Vijver MJ, He YDD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH |
| Source: NATURE Volume: 415 Issue: 6871 Pages: 530-536 Published: JAN 31 2002 |
| Times Cited: 2,651 References: 26 |
| Abstract: Breast cancer patients with the same stage of disease can have markedly different treatment responses and overall outcome. The strongest predictors for metastases (for example, lymph node status and histological grade) fail to classify accurately breast tumours according to their clinical behaviour(1-3). Chemotherapy or hormonal therapy reduces the risk of distant metastases by approximately one-third; however 70-80% of patients receiving this treatment would have survived without it(4,5). None of the signatures of breast cancer gene expression reported to date(6-12) allow for patient-tailored therapy strategies. Here we used DNA microarray analysis supervised classification to identify a gene expression signature strongly predictive of a short interval to distant metastases ('poor prognosis' signature) in patients without tumour cells in local lymph nodes at diagnosis (lymph node negative). In addition, we established a signature that identifies tumours of BRCA1 carriers. The poor prognosis signature consists of genes regulating cell cycle, invasion, metastasis and angiogenesis. This gene expression profile will outperform all currently used clinical parameters in predicting disease outcome. Our findings provide a strategy to select patients who would benefit from adjuvant therapy. |
| Document Type: Article |
| Language: English |
| Reprint Address: Friend, SH (reprint author), Rosetta Inpharmat, 12040 115th Ave NE, Kirkland, WA 98034 USA |
Addresses:
1. Rosetta Inpharmat, Kirkland, WA 98034 USA
2. Netherlands Canc Inst, Div Diagnost Oncol, NL-1066 CX Amsterdam, Netherlands
3. Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands
4. Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands |
| Publisher: NATURE PUBLISHING GROUP, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND |
| Subject Category: Multidisciplinary Sciences |
| IDS Number: 516PQ |
| ISSN: 0028-0836 |
|
| | | | | | | | | Record from Web of Science® | | | | | | | | | |